- Diabetes Mellitus
    - [Inpatient Management](https://www.ccjm.org/content/83/5_suppl_1/S34){:target="_blank"}
    - [ACCORD: A1c target <6.0% increased CV and all-cause mortality vs standard (7.0-7.9%)](https://www.nejm.org/doi/full/10.1056/nejmoa0802743){:target="_blank"}
    - [RABBIT-2: Basal-Bolus > SSI](https://pubmed.ncbi.nlm.nih.gov/17513708/){:target="_blank"}
    - [FREEDOM: All-cause mortality is improved with CABG > PCI w/DES in T2DM](https://pubmed.ncbi.nlm.nih.gov/18215589/){:target="_blank"}
    - [NICE-SUGAR: Intensive glucose control increased mortality in ICU patients](https://pubmed.ncbi.nlm.nih.gov/19318384/){:target="_blank"}
    - [CREDENCE: Canagliflozin 100mg/d reduces risk of ESRD and death](https://pubmed.ncbi.nlm.nih.gov/30990260/){:target="_blank"}
- DKA
    - [Management](https://pubmed.ncbi.nlm.nih.gov/25061324/){:target="_blank"}
- Hypothyroidism
    - [Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association](https://pubmed.ncbi.nlm.nih.gov/23246686/){:target="_blank"}
    - Labs
        - TSH then Free Thyroxine (FT4)
            - TSH elevated: overt/subclinical
            - FT4 low: overt only
        - T3 recommended if any:
            - Evaluation of thyrotoxicosis
            - T3 Toxicosis: T3:T4 > 20
        - Assess severity of hyperthyroidism and response to therapy
        - Differentiate hyperthyroidism from destructive thyroidism
            - T3 if low
            - https://pubmed.ncbi.nlm.nih.gov/21510801/
            - https://pubmed.ncbi.nlm.nih.gov/1569166/
- Hyperthyroidism
    - [General](https://pubmed.ncbi.nlm.nih.gov/21510801/){:target="_blank"}